Cybin Inc. (NYSE American: CYBN) (NEO: CYBN), a clinical-stage biopharmaceutical company, has announced that its CEO, Doug Drysdale, will participate in a panel titled 'The Global Landscape and Opportunities for Medical Breakthroughs' at the 28th Annual Milken Institute Global Conference. Scheduled for May 5 at 2:30 p.m. PDT, the discussion will focus on innovation in drug development and next-generation mental health treatments, underscoring the potential of psychedelic-based therapeutics in addressing mental health conditions.
The event, taking place at the Beverly Hilton in Los Angeles, will be accessible via live stream and replay on Cybin’s investor website. This participation marks a significant moment for Cybin as it seeks to advance its mission of revolutionizing mental healthcare through the development of safe and effective psychedelic-based treatments. The company is currently developing CYB003, a proprietary deuterated psilocybin analog for major depressive disorder, and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder, among other investigational compounds.
Cybin's presence at the Milken Institute Global Conference reflects the increasing recognition of psychedelic-based therapeutics as a viable solution to the unmet needs in mental health treatment. With a network of world-class partners and scientists, Cybin is at the forefront of exploring innovative drug delivery systems and formulation approaches. The panel discussion will provide insights into the opportunities and challenges in the psychedelic industry, offering valuable perspectives for investors, healthcare professionals, and patients alike.
For more details on Cybin's initiatives and to view the press release, visit https://ibn.fm/VL8Zf. Cybin's commitment to advancing mental health treatments through psychedelic-based therapeutics underscores the potential for significant impact on the industry and patients worldwide.
